Vertex inches closer to acute pain market with FDA application acceptance

Vertex Pharmaceuticals has inched closer to bringing a new, non-opioid med to the blockbuster pain market, with the FDA accepting a rolling new drug application for the company’s NaV1.8 inhibitor VX-548 in moderate-to-severe acute pain.